TrustRadius: an HG Insights company

Cloudbyz Safety and Pharmacovigilance (PV) vs. Oracle Argus

Save this comparison

Save this comparison

Add Product

Recommended Comparisons

    Overview
    ProductRatingMost Used ByProduct SummaryStarting Price

    Cloudbyz Safety and Pharmacovigilance (PV)

    N/AN/ACloudbyz Safety & Pharmacovigilance Solution is a cloud-based software solution designed to streamline the drug safety and pharmacovigilance operations for pharmaceutical and life science companies. The solution helps to automate the process of collecting, processing, analyzing and reporting adverse event data in compliance with global regulatory requirements. Cloudbyz Safety & Pharmacovigilance Solution helps companies to reduce risk, improve compliance, and enhance patient safety while…N/A

    Oracle Argus

    Score8.3 out of 10
    N/AArgus, by Oracle, is a solution for processing, analyzing, and reporting adverse event cases originating in pre- and post-market drugs, biologics, vaccines, devices, and combination products. Built-in Argus automation features—for intake, case prioritization, field validations, letters, action items, coding, listedness, narratives, case lock, submission, and archiving—can reduce manual work.N/A
    Pricing
    Cloudbyz Safety and Pharmacovigilance (PV)Oracle Argus
    Editions & Modules
    No answers on this topic
    No answers on this topic
    Offerings
    Pricing Offerings
    Cloudbyz Safety and Pharmacovigilance (PV)Oracle Argus
    Free Trial
    YesNo
    Free/Freemium Version
    NoNo
    Premium Consulting/Integration Services
    NoNo
    Entry-level Setup FeeRequiredNo setup fee
    Additional Details
    More Pricing Information
    Best Alternatives
    Cloudbyz Safety and Pharmacovigilance (PV)Oracle Argus
    Small Businesses
    No answers on this topic
    Bonterra Apricot
    Score9.5 out of 10
    Medium-sized Companies
    No answers on this topic
    Bonterra Apricot
    Score9.5 out of 10
    Enterprises
    No answers on this topic
    No answers on this topic
    All AlternativesView all alternativesView all alternatives